Buy XXII by Nov 29, 2026.

As the exclusive leader in FDA-authorized, reduced-nicotine combustible cigarettes, 22nd Century Group, Inc. (Nasdaq: XXII) is rapidly scaling its national footprint. Backed by an improving balance sheet, the company’s strategic shift toward high-margin product lines provides a highly compelling catalyst for investors tracking disruptive micro-cap equities. Aggressive Retail Expansion 22nd Century is executing a disciplined rollout of its flagship VLN® and Pinnacle® brands, aggressively expanding market access and driving consumer trial across major U.S. markets. The company's recent operational milestones …